Latham & Watkins Advises Solace Health in US$130 Million Series C Funding Round

Solace Health has announced a US$130 million Series C funding round led by IVP, accelerating the company’s mission to make advocacy a standard part of care for every patient in the United States. The Series C values Solace at over US$1 billion and reflects growing consensus that healthcare advocacy is no longer optional as costs rise and systems fracture. The round also included participation from existing investors Menlo Ventures, SignalFire, Torch Capital, Inspired Capital, and RiverPark Ventures.

Latham & Watkins LLP represented Solace Health in the transaction with a corporate team led by Bay Area partner Alex Kassai, with associates Alec Hampton, Saul Aguirre‑Villarreal, and Chris Pham. Assistance was also provided on the regulatory side by Washington, D.C. counsel Nicole Liffrig Molife and Los Angeles counsel Yanyan Zhou; and on the data privacy side by San Diego/San Francisco counsel Jennifer Howes, with associate Zac Alpert.